These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 17258563)

  • 1. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R; Taron M; Alberola V; Massuti B; Felip E
    Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
    Jensen PB; Holm B; Sorensen M; Christensen IJ; Sehested M
    Br J Cancer; 1997; 75(6):869-77. PubMed ID: 9062409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
    Luo J; Leaw SJ; Xu Y; Zheng D
    Med Oncol; 2011 Dec; 28(4):1418-24. PubMed ID: 20661668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
    Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR
    Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
    J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
    Tanvetyanon T; Lee JH; Fulp WJ; Schreiber F; Brown RH; Levine RM; Cartwright TH; Abesada-Terk G; Kim GP; Alemany C; Faig D; Sharp PV; Markham MJ; Malafa M; Jacobsen PB
    J Oncol Pract; 2015 Jul; 11(4):332-7. PubMed ID: 25991639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Heo SJ; Jung I; Lee CK; Kim JH; Lim SM; Moon YW; Shim HS; Jeong J; Kim JH; Kim HR; Cho BC
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):539-48. PubMed ID: 26811178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer.
    d'Amato TA; Landreneau RJ; McKenna RJ; Santos RS; Parker RJ
    Ann Thorac Surg; 2006 Feb; 81(2):440-6; discussion 446-7. PubMed ID: 16427828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of docetaxel in advanced non-small-cell lung cancer.
    Belani CP; Eckardt J
    Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
    Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
    Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
    Stewart DJ; Tomiak E; Shamji FM; Maziak DE; MacLeod P
    Lung Cancer; 2004 May; 44(2):241-9. PubMed ID: 15084389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
    Ornstein DL; Nervi AM; Rigas JR
    Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
    Bunn PA
    Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.